Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

被引：0

作者：

Sharma, Padmanee

Krainer, Michael

Saad, Fred

Castellano, Daniel

Bedke, Jens

Kwiatkowski, Mariusz

Patnaik, Akash

Procopio, Giuseppe

Wiechno, Pawel

Kochuparambil, Samith Thomas

Thomas, Christian

Arija, Jose Angel Arranz

McCune, Steven L.

Hansen, Steinbjorn

Daugaard, Gedske

Amin, Neha P.

Wang, Yumeng

David, Justin M.

Pachynski, Russell Kent

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Med Univ Vienna, Vienna, Austria

[3] Univ Montreal Hosp Ctr, Montreal, PQ, Canada

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] Eberhard Karls Univ Tubingen, Tubingen, Germany

[6] Szpital Wojewodzki Mikolaja Kopernika w Koszalini, Oddzial Dzienny Chemioterapii, Koszalin, Poland

[7] Univ Chicago Med, Chicago, IL USA

[8] Ist Nazl Tumori Milano, Milan, Italy

[9] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[10] Minnesota Oncol, Minneapolis, MN USA

[11] Natl Ctr Tumor Dis, Heidelberg, Germany

[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[13] Northwest Georgia Oncol Ctr, Marietta, GA USA

[14] Odense Univ Hosp, Odense, Denmark

[15] Rigshosp, Univ Copenhagen Hosp, Copenhagen, Denmark

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Washington Univ, Sch Med, St Louis, MO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[1] Initial Results From a Phase 2 Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 8 - 10
[2] Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
Sharma, Padmanee
Pachynski, Russell Kent
Narayan, Vivek
Flechon, Aude
Gravis, Gwenaelle
Galsky, Matt D.
Mahammedi, Hakim
Patnaik, Akash
Subudhi, Sumit Kumar
Ciprotti, Marika
Duan, Tao
Saci, Abdel
Hu, Sarah
Han, G. Celine
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[3] Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Sharma, Padmanee
Pachynski, Russell K.
Narayan, Vivek
Flechon, Aude
Gravis, Gwenaelle
Galsky, Matthew D.
Mahammedi, Hakim
Patnaik, Akash
Subudhi, Sumit K.
Ciprotti, Marika
Simsek, Burcin
Saci, Abdel
Hu, Yanhua
Han, G. Celine
Fizazi, Karim
CANCER CELL, 2020, 38 (04) : 489 - +
[4] Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Fizazi, Karim
Retz, Margitta
Petrylak, Daniel P.
Goh, Jeffrey C.
Perez-Gracia, Jose
Lacombe, Louis
Zschabitz, Stefanie
Burotto, Mauricio
Mahammedi, Hakim
Gravis, Gwenaelle
Bastos, Diogo Assed
McCune, Steven L.
Limon, Juan Carlos Vazquez
Kwan, Edmond M.
Castellano, Daniel
Flechon, Aude
Saad, Fred
Grimm, Marc-Oliver
Shaffer, David R.
Armstrong, Andrew J.
Bhagavatheeswaran, Prabhu
Amin, Neha P.
Unsal-Kacmaz, Keziban
Wang, Xuya
Li, Jun
Loehr, Andrea
Pachynski, Russell K.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
[5] CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) plus rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
Pachynski, Russell Kent
Retz, Margitta
Goh, Jeffrey C.
Burotto, Mauricio
Gravis, Gwenaelle
Castellano, Daniel
Flechon, Aude
Zschaebitz, Stefanie
Shaffer, David R.
Limon, Juan Carlos Vazquez
Grimm, Marc-Oliver
McCune, Steven L.
Amin, Neha P.
Li, Jia
Wang, Xuya
Unsal-Kacmaz, Keziban
Saad, Fred
Petrylak, Daniel P.
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Nivolumab Plus Docetaxel in Patients With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Results From the Phase II Checkmate 9KD Trial
Fizazi, K.
Mella, P. Gonzalez
Castellano, D.
Minatta, J. N.
Kalebasty, A. R.
Shaffer, D.
Limon, J. C. Vazquez
Lopez, H. M. Sanchez
Armstrong, A. J.
Horvath, L.
Bastos, D. A.
Amin, N. P.
Li, J.
Unsal-Kacmaz, K.
Retz, M.
Saad, F.
Petrylak, D. P.
Pachynski, R. K.
JOURNAL OF UROLOGY, 2023, 209 (02): : 445 - 446
[7] Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
Hussain, M.
Smith, M. R.
Sweeney, C.
Corn, P. G.
Elfiky, A.
Gordon, M. S.
Haas, N. B.
Harzstark, A. L.
Kurzrock, R.
Lara, P.
Lin, C.
Sella, A.
Small, E. J.
Spira, A. I.
Vaishampayan, U. N.
Vogelzang, N. J.
Scheffold, C.
Ballinger, M. D.
Schimmoller, F.
Smith, D. C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[8] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
Clarke, Noel
Wiechno, Pawel J.
Alekseev, Boris
Sala, Nuria
Jones, Robert
Kocak, Ivo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort
Tsimberidou, Apostolia M.
Drakaki, Alexandra
Khalil, Danny N.
Okrah, Kwame
Schachter, Mike
Gautam, Shikha
Da Silva, Diane M.
Alayli, Farah A.
Spencer, Christine N.
Foo, Wai Chin
Adamow, Matthew
Wong, Phillip
Fairchild, Justin
Arnott, Jamie
Dugan, Ute
Boffo, Silvia
Salvador, Lisa
Cabanski, Christopher R.
Subudhi, Sumit K.
Sharma, Padmanee
CANCER RESEARCH, 2024, 84 (07)
[10] A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)
Drake, C. G.
Saad, F.
Clark, W. R.
Ciprotti, M.
Sharkey, B.
Subudhi, S. K.
Fizazi, K.
ANNALS OF ONCOLOGY, 2020, 31 : S546 - S546

← 1 2 3 4 5 →